Compare Citius Pharmaceuticals Inc (CTXR) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Energy Select Sector SPDR Fund — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Energy Select Sector SPDR Fund trades at $65.09 (market cap $40.84B). The key difference: Energy Select Sector SPDR Fund is far larger — about 2998.5× Citius Pharmaceuticals Inc's market cap, and Energy Select Sector SPDR Fund is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Energy Select Sector SPDR Fund for 67 Days on average.
| CTXR | XLE | |
|---|---|---|
Market Cap | $13.62M | $40.84B |
Volume | 132,438 | 50,409,268 |
Sector | Health | — |
52-Week High | $1.82 | $65.93 |
52-Week Low | $0.48 | $42.61 |
Typical Hold Time | 17 Days | 67 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
XLE trades at $65.24, up 2.93% with strong bullish momentum from moving averages but overbought RSI signals. The energy ETF benefits from oil price surges above $100 and Middle East tensions, though futures traders bet on a 12% sector decline. Dividend yield remains modest with a $0.38 distribution scheduled for September 2026.
Outlook hinges on oil price sustainability amid geopolitical risks and Fed policy. Key risks include oil volatility and strategic reserve releases. Analysts show mixed signals with technical strength but fundamental data gaps warrant caution for energy sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
